{"path":"Images/Pasted image 20231007145431.png","text":"PULMONARY EMBOLISM TREATMENT by nick Markuo onepagericuom Lo [lisHE L ONE 1 o Gricanmark ™5 3 Ideally choosing the intervention version > [a]3 is a multi-disciplinary discussion Exclude contraindications, Indications: — - (eg. PERT teom o Masive PE (defnie indcation) Diagnosis and + Anticoagulation DAL ESET Systemic . yigh risk submassive PE (risk/benefit) risk assessment intervention icu thrombolysis std dose alteplase = 100mg IV over 2 hrs Physcalexam, CT scan, LMWH SC preferable but use For patients w/ massive or Low dose 0.5 me/kg (up to Some V) POCUS, EKG, Iabs VG, UFH gt for patients at high rsk high ik sub-massive PE B ton (et otner malor lactate, troponin, BNP), & for requiring thrombolysis (it € calculate risk score using an can be turned off promptly) Optimize Catheter Useful in patients who are higher risk for ‘onine calutator ~hemodynamics _ thrombolysis. May be superio to antcoag i directedlysis .\\o. in intermediate risk PE. Exam; Tachypnea, VD, loud P2, 53/4 gallop, diaphoresis,fever, hemoptysis For patients in shock EKG: Sinus tach, QR in V1, RBBB, TWI V1-4, STE V1-4, 5:Qsla May be usefulin patients who fail above T eflux of contrastinto IVC, PA > 30 mim, PA > Ao, RV bowing; sadle £ l Embolectomy therspies,who have C/I o thrombolysis, o not associated with incregsed mortality or who require surgery for large RA thrombus POCUS; RV/LV diameter > 0.9, McConnel Sign,septa flatening, dilated . rewEs IVC, decreased TAPSE, cot in transit Optimize B patents do ot redure I xcess PE Mimics: post MI VSD, non-thrombotic E (fat, air, tumor, septic, foreign Preload P > g matter, etc.), chronic PE, severe PAH unless clear evidence of lemia 1 Ppocus ot - Ifiow €O, onsider use of Risk prognostication based on scores and clinial features: T e NTERMEDIATE | HIGHrisk | [ contractitity monitorfor hypoTN Bovascore g.g 3.2 57 Inotrope - Keep SpO2 > 90% w/ supp O2. Sodaypereaes 1 o o) Optimize ,qid intubation i possible. mortal ‘oxygenation intut ; avoil pesidass 11 \" w v e e ot 0l J0doyollcouse ey g)(1735%) (3271%) (40115%) (100245%) - consider low TV (6-8 cc/kg) mortalty S Treat reversible RV dysfunction AV pn A4CRY diameter ivided by LV diameter 50.3; coes . TAbSE < 6, H or AND. AND. Reduce PVR Pul 3 somarkers Elevated Cardiac Biomarkers imonary BNP > S00rN-terminal pro-BNP > 500 im s Tong votome “Tnl > 0.4 ng/mi or TnT > 0.1 ng/ml Inhaled pulmonary Optimize Acidosis willincrease PVR. : Massive PE vasadiators (rostacycins > B ust ventiation to correct ’ Stable Transient || g ooeghem o INO) can decrease PVR Hemodynomics| - hemodynamics (15 i, shock o intai v YPOTN | i minh shoek Maintain ¢ peristent hypoT, use a vasopressor that does afterload not increase PAP: vasopressin, epinephrine, NE [ mwh | g k__ o } = o7 ? H 72 Tretment s ZBOMBONSIS_} o patnts withprsstent sk st 2 T bl thrombolyss; consider VA ECMO ~ B . ECMO - — a02","libVersion":"0.3.2","langs":"eng"}